A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Aducanumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms PRIME
  • Sponsors Biogen
  • Most Recent Events

    • 28 Aug 2017 Results from the placebo-controlled period and the long-term extension for patients treated with aducanumab up to 24 months in the titration cohort and up to 36 months in the fixed-dose cohorts published in a Biogen media release.
    • 20 Jul 2017 Results of a post-hoc analysis assessing cognitive and functional domains of the CDR at the week 54, presented at the Alzheimer's Association International Conference 2017
    • 14 Jul 2017 According to a Biogen media release, data will be presented at the Alzheimer's Association International Conference (AAIC) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top